Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breas
Updated results of a Phase III study of Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing.